investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
CAMBRIDGE, Mass. & MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioningRead more
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for patients with sickle cell disease New data from ongoing Phase 3 studies of LentiGlobin™Read more
- Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process - - Ended quarter with $1.41 billion in cash, cashRead more